Research programme: broad spectrum anticonvulsants - Johnson & JohnsonAlternative Names: JNJ-26990990
Latest Information Update: 25 Mar 2010
At a glance
- Originator Johnson & Johnson
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical CNS disorders; Diabetes mellitus; Epilepsy; Major depressive disorder; Metabolic disorders; Migraine; Neuropathic pain; Obesity
Most Recent Events
- 25 Mar 2010 Preclinical development is ongoing in USA